PGY-5 Resident @UChicagoRadOnc. I endorse RT but RTs are not endorsements.
Joined September 2022
- Tweets15
- Following43
- Followers35
- Likes22
Online now: our report in EJC compiles toxicity data from 213 pts across 3 multi-site SBRT + immune checkpoint inhibitor trials at UChicago to characterize the toxicity profile of combined modality treatment: sciencedirect.com/science/ar…
We found rates of toxicity were similar to those seen in major trials of ICI alone, suggesting that SBRT adds minimal toxicity (consistent with low rates of SBRT tox in SABR-5 and recently OligoCare). Critically, standard SBRT constraints were used with priority on OAR sparing.
Thanks to @ajuloorimd, @mkorps42, @RohanKatipally, @SeanPitroda, @Docace911, @ChristineBestv1, @jasonlukemd, and @JPatelMD for contributions to this work!
Connor Lynch retweeted
New Review in the August issue: Radiotherapy, immunity, and immune checkpoint inhibitors
#radiotherapy #ImmuneCheckpointInhibitors
thelancet.com/journals/lanon…
Considering negative trials of radiation and immunotherapy in light of available preclinical and translational data. Our review of this rapidly evolving field: sciencedirect.com/science/ar…
Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: ascopubs.org/doi/10.1200/JCO… (thanks to @rweichselbaum @MuzamilArshad18 @RohanKatipally @SeanPitroda)
More interesting findings from UChicago Chem and Rad Onc (@rweichselbaum lab) on STING activation and the tumor microenvironment science.org/doi/full/10.1126…
Connor Lynch retweeted
Thanks for the shoutout! One of the great things about training @UChicagoRadonc is working with cool data like this. Looking at our SBRT/ICI trial data we realized we had a kind of natural experiment going on (ICI w/ or w/o liver met SBRT).